8696879946_c47d0f98fa_o.jpg
cells14.jpg
cells1.jpg
8696879946_c47d0f98fa_o.jpg

Let us teach you about biotech finance and clinical trials!


SCROLL DOWN

Let us teach you about biotech finance and clinical trials!


WEB_PG_ICTR.jpg
 

COMING IN Q1-2020

THE PHARMAGELLAN GUIDE TO INTERPRETING CLINICAL TRIAL RESULTS is a complete and concise reference to help you make sense of drug and device trials. Intended for non-statisticians, it’s chock-full of “news you can use" as your read companies’ press releases, abstracts, investor presentations, and publications, plus more detailed references if you want to dig deeper into methodology issues.

 

This new book will be published in Q1-2020 — but sign up today to receive regular updates, plus a pre-order discount offer later this year!

SIGN UP HERE FOR MORE INFO AND OTHER GOODIES!

 
 

BUY IT on amazon

THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is your one-stop reference to make investment decisions, pitch to potential partners, or estimate the value of an R&D program.

 

"Deserves a spot on the bookshelf of every biotech CFO."

- Bruce Booth, Partner, Atlas Venture

 

Learn how to get a free sample chapter on “Projecting Market Share for R&D-Stage Biotechs” here

cells14.jpg

Discover how far you can go.


SCROLL DOWN

Discover how far you can go.


 

Pharmagellan unlocks the true value in your biotech development pipeline.


Many early-stage drug development projects don't progress if the team is stretched thin, and people and resources are focused on more advanced assets.

To fully realize the value of projects under development, these companies need external support that is both senior-level and hands-on.

Pharmagellan offers just that: expert advice and project execution to biotech and pharma companies willing to discover how far they can go. Learn more about what we do and how we can help.

 


Research
& Development

Preclinical, translational, and early clinical strategy and execution

 

commercial
& Corporate

Competitive and financial analysis of products, portfolios, and companies

 
cells1.jpg

Research highlights


SCROLL DOWN

Research highlights